PRODIGE 7 should be interpreted with caution.

PRODIGE 7 should be interpreted with caution. Acta Chir Belg. 2019 Apr 23;:1-13 Authors: Liberale G, Ameye L, Hendlisz A Abstract The recent presentation and abstract from the PRODIGE 7 study at ASCO 2018 on the role of hyperthermic intraperitoneal chemotherapy (HIPEC) using oxaliplatin as adjuvant treatment following cytoreductive surgery (CRS) in patients with colorectal peritoneal metastases (PM) who have received perioperative chemotherapy (PCT) has shaken the surgical community involved in the treatment of colorectal PM. Since then, two papers, an editorial and an opinion paper, have been reported in response to the results from PRODIGE 7 with opposite conclusions and perspectives. In this debate paper, we focus on methodological aspects of the PRODIGE 7 trial by pointing out several weaknesses of the study, such as inclusion criteria (PCI >16) and the power calculation, in an effort to highlight our perspective that these results should be interpreted with caution and in the context of objective information in the current literature. PMID: 31010391 [PubMed - as supplied by publisher]
Source: Acta Chirurgica Belgica - Category: Surgery Tags: Acta Chir Belg Source Type: research